GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
View Patent ↗In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).
1. A method of delaying the onset of Type I diabetes, and/or slowing the progression of, and/or reducing the severity of diabetes in a mammal, said method comprising coadministering to said mammal:
a first compound comprising gamma-aminobutyric acid (GABA); and
a second compound comprising sitagliptin and, optionally, an immunosuppressant;
wherein said first compound and said second compound are administered in an amount sufficient to delay the onset of diabetes, and/or slow the progression of diabetes, and/or reduce the severity of diabetes in said mammal.
2. A method of delaying the onset of hyperglycemia, and/or slowing the progression of hyperglycemia, and/or reducing the severity of hyperglycemia, said method comprising coadministering to said mammal:
a first compound comprising gamma-aminobutyric acid (GABA); and
a second compound comprising sitagliptin and, optionally, an immunosuppressant;
wherein said first compound and said second compound are administered in an amount sufficient to delay the onset of hyperglycemia, and/or slow the progression of hyperglycemia, and/or reduce the severity of hyperglycemia in said mammal.
3. A method of promoting transplanted islet cell survival in a mammal having Type I diabetes or at risk for type I diabetes who is a recipient of transplanted islet cells, said method comprising coadministering to said mammal:
a first compound comprising gamma-aminobutyric acid (GABA); and
a second compound comprising sitagliptin and, optionally, an immunosuppressant;
wherein said first compound and said second compound are administered in an amount sufficient to promote transplanted islet cell survival in said mammal.
4. A method of delaying the onset of an immune response, and/or slowing the progression of an immune response, and/or reducing the severity of an immune response, and/or suppressing an immune response in a mammal, said method comprising coadministering to said mammal:
a first compound comprising gamma-aminobutyric acid (GABA); and
a second compound comprising sitagliptin and, optionally, an immunosuppressant;
wherein said first compound and said second compound are administered in an amount sufficient to delay the onset of an immune response, and/or slow the progression of an immune response, and/or reduce the severity of an immune response, and/or suppress an immune response in said mammal.
5. A method of protecting beta-cells in a mammal from oxidative stress induced apoptosis said method comprising coadministering to said mammal:
a first compound comprising gamma-aminobutyric acid (GABA); and
a second compound comprising sitagliptin and, optionally, an immunosuppressant;
wherein said first compound and said second compound are administered in an amount sufficient to partially or fully protect said beta cells from oxidative stress induced apoptosis.